Switching from Abilify Maintena 400 mg to Uzedy
When switching from Abilify Maintena 400 mg monthly injection to Uzedy, you must first establish oral risperidone tolerability, then initiate Uzedy the day after the last oral risperidone dose—no loading doses or oral supplementation are needed. 1
Critical First Step: Establish Tolerability
Before any switch to Uzedy can occur, you must establish tolerability with oral risperidone 1. This is an FDA-mandated requirement and cannot be bypassed. The patient should take oral risperidone for a sufficient period to assess for adverse reactions, particularly extrapyramidal symptoms, metabolic effects, and hypotension.
The Switching Protocol
Step 1: Transition to Oral Risperidone
- Discontinue Abilify Maintena 400 mg
- Given aripiprazole's long half-life from the LAI formulation, initiate oral risperidone approximately 4-6 weeks after the last Abilify Maintena injection to allow for gradual washout while maintaining antipsychotic coverage 2, 3
- Start with oral risperidone 2-4 mg daily (adjust based on clinical response and tolerability)
- Continue oral risperidone for at least 1-2 weeks to establish tolerability
Step 2: Determine Uzedy Dose
Once tolerability is confirmed, select the appropriate Uzedy dose based on the oral risperidone dose the patient has been stabilized on 1:
For Monthly Dosing:
- Oral risperidone 2 mg daily → Uzedy 50 mg monthly
- Oral risperidone 3 mg daily → Uzedy 75 mg monthly
- Oral risperidone 4 mg daily → Uzedy 100 mg monthly
- Oral risperidone 5 mg daily → Uzedy 125 mg monthly
For Every-2-Month Dosing:
- Oral risperidone 2 mg daily → Uzedy 100 mg every 2 months
- Oral risperidone 3 mg daily → Uzedy 150 mg every 2 months
- Oral risperidone 4 mg daily → Uzedy 200 mg every 2 months
- Oral risperidone 5 mg daily → Uzedy 250 mg every 2 months
Step 3: Initiate Uzedy
- Administer the first Uzedy injection the day after the last oral risperidone dose 1
- No loading doses are required
- No oral supplementation is needed 1
- Administer subcutaneously in the abdomen or upper arm
Important Pharmacological Considerations
Antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication 4. Aripiprazole (a D2 partial agonist) and risperidone (a D2 antagonist) have fundamentally different pharmacodynamic profiles, making this transition particularly important to manage carefully.
Key Differences to Monitor:
- Metabolic effects: Risperidone carries significantly higher risk of weight gain and metabolic disturbances compared to aripiprazole 5. In a recent randomized trial, risperidone caused mean BMI increases of +1.1 kg/m² versus +0.4 kg/m² with aripiprazole over 7 weeks (p < 0.001) 5
- Appetite changes: Expect increased appetite with risperidone (55.2% of patients) versus decreased appetite with aripiprazole (60.7%) 5
- Extrapyramidal symptoms: Risperidone has higher risk of drug-induced Parkinsonism and akathisia compared to aripiprazole 2
Common Pitfalls to Avoid
Do NOT skip oral tolerability testing - This is an FDA requirement and prevents serious adverse reactions 1
Do NOT initiate Uzedy too soon after stopping Abilify Maintena - The aripiprazole LAI has a prolonged release profile; starting risperidone immediately risks excessive dopamine blockade during the overlap period
Do NOT use loading doses or oral supplementation - Unlike some other LAI transitions, Uzedy's pharmacokinetic profile does not require this 1
Do NOT forget to counsel about metabolic monitoring - Implement baseline and ongoing monitoring of weight, waist circumference, blood pressure, fasting glucose, and lipid panel given risperidone's metabolic liability 5
Clinical Monitoring During Transition
Monitor closely during the first 4-8 weeks for:
- Symptom breakthrough or relapse (due to different receptor profiles)
- Extrapyramidal symptoms (higher risk with risperidone)
- Weight gain and increased appetite (common with risperidone)
- Orthostatic hypotension (especially during oral risperidone phase)
- Prolactin elevation (risperidone has significant prolactin-elevating effects unlike aripiprazole)
If the patient develops intolerable side effects during oral risperidone tolerability testing, do not proceed with Uzedy - consider alternative LAI options or return to aripiprazole-based therapy 1.